| Evaluating UTI Outcomes in at Risk Populations (NCT05385536) | Pathnostics | 2022-07-18 |
| Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (NCT04876131) | Murdoch Childrens Research Institute | 2022-05-30 |
| Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections (NCT05060419) | Qilu Pharmaceutical Co., Ltd. | 2021-10-08 |
| Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis (NCT05674032) | Thomayer University Hospital | 2020-06-24 |
| Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions. (NCT04076436) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2019-10-21 |
| Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (NCT03788967) | Spero Therapeutics | 2019-06-03 |
| MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) (NCT03230838) | Merck Sharp & Dohme LLC | 2018-04-26 |
| Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections (NCT03445195) | Entasis Therapeutics | 2018-01-17 |
| Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) (NCT03293485) | Merck Sharp & Dohme LLC | 2017-10-04 |
| Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) (NCT02728089) | Merck Sharp & Dohme LLC | 2016-04-14 |
| A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (NCT02486627) | Achaogen, Inc. | 2016-01-11 |
| Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens (NCT01644643) | Pfizer | 2013-01-01 |
| Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care (NCT02024282) | KU Leuven | 2013-01-01 |
| Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis (NCT01345929) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2011-06-20 |
| A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) (NCT01096849) | Achaogen, Inc. | 2010-07-13 |
| Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections (NCT00921024) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2009-06-30 |
| Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections (NCT00690378) | Pfizer | 2008-11-01 |
| Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection (NCT04682834) | Iterum Therapeutics, International Limited | |